Reference
·Supporting source
Thailand Precision Medicine Market Size — 2027 Projection
~THB 12-19B (base ~THB 15B)
Insight Research estimates Thailand's precision-medicine market (companion diagnostics, pharmacogenomics, liquid biopsy, polygenic risk scores) reaches THB 12-19B by end-2027 versus a THB 3-5B 2024 baseline, with a base-case landing at approximately THB 15B. Growth is reimbursement-led for the first time: NHSO Universal Coverage adds priority CDx panels into oncology bundles across FY2026-2027, Thai FDA finalises an NGS CDx regulatory framework Q4 2026, Genome Thailand reaches a 50,000 whole-genome cohort milestone, and lab capacity at Bangkok Genomics, Asia Genomics, Geneus DNA, Quantum Tech, and iBiotech scales four to six times. Six operators (BDMS, Bumrungrad, BNH, Bangkok Genomics, Asia Genomics, Geneus DNA) plus Vejthani and Quantum Tech capture more than 70% of 2026 spend, and medical-tourism patients drive 35-50% of revenue at the hospital-integrated centres.
Figure in context
Insight Research estimates Thailand's precision-medicine market (companion diagnostics, pharmacogenomics, liquid biopsy, polygenic risk scores) reaches THB 12-19B by end-2027 versus a THB 3-5B 2024 baseline, with a base-case landing at approximately THB 15B. Growth is reimbursement-led for the first time: NHSO Universal Coverage adds priority CDx panels into oncology bundles across FY2026-2027, Thai FDA finalises an NGS CDx regulatory framework Q4 2026, Genome Thailand reaches a 50,000 whole-genome cohort milestone, and lab capacity at Bangkok Genomics, Asia Genomics, Geneus DNA, Quantum Tech, and iBiotech scales four to six times. Six operators (BDMS, Bumrungrad, BNH, Bangkok Genomics, Asia Genomics, Geneus DNA) plus Vejthani and Quantum Tech capture more than 70% of 2026 spend, and medical-tourism patients drive 35-50% of revenue at the hospital-integrated centres.
Insight Research estimates Thailand's precision-medicine market (companion diagnostics, pharmacogenomics, liquid biopsy, polygenic risk scores) reaches THB 12-19B by end-2027 versus a THB 3-5B 2024 baseline, with a base-case landing at approximately THB 15B. Growth is reimbursement-led for the first time: NHSO Universal Coverage adds priority CDx panels into oncology bundles across FY2026-2027, Thai FDA finalises an NGS CDx regulatory framework Q4 2026, Genome Thailand reaches a 50,000 whole-genome cohort milestone, and lab capacity at Bangkok Genomics, Asia Genomics, Geneus DNA, Quantum Tech, and iBiotech scales four to six times. Six operators (BDMS, Bumrungrad, BNH, Bangkok Genomics, Asia Genomics, Geneus DNA) plus Vejthani and Quantum Tech capture more than 70% of 2026 spend, and medical-tourism patients drive 35-50% of revenue at the hospital-integrated centres.
Time scope
Projection to 2027
Source basis
Supporting source
Interpretation notes
What this tells you
Insight Research estimates Thailand's precision-medicine market (companion diagnostics, pharmacogenomics, liquid biopsy, polygenic risk scores) reaches THB 12-19B by end-2027 versus a THB 3-5B 2024 baseline, with a base-case landing at approximately THB 15B. Growth is reimbursement-led for the first time: NHSO Universal Coverage adds priority CDx panels into oncology bundles across FY2026-2027, Thai FDA finalises an NGS CDx regulatory framework Q4 2026, Genome Thailand reaches a 50,000 whole-genome cohort milestone, and lab capacity at Bangkok Genomics, Asia Genomics, Geneus DNA, Quantum Tech, and iBiotech scales four to six times. Six operators (BDMS, Bumrungrad, BNH, Bangkok Genomics, Asia Genomics, Geneus DNA) plus Vejthani and Quantum Tech capture more than 70% of 2026 spend, and medical-tourism patients drive 35-50% of revenue at the hospital-integrated centres.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Genome Thailand Cohort Size — 2026 Milestone
DMSc Genome Thailand programme documents, NIH-DMSc, MoPH
NHSO Priority CDx Panels Added to Oncology Bundles — FY2026-2027
NHSO National List of Essential Medicines planning documents, NHSO public consultations, hospital partner disclosures
Thailand Hospital-Integrated Personalised Cancer Package ASP
BDMS, Bumrungrad, BNH, Vejthani programme disclosures, Insight Research triangulation
Thailand Precision Medicine Test-Type Mix — 2026 Estimate
Lab operator filings, hospital programme disclosures, NHSO planning documents, Insight Research triangulation
Thailand Precision Medicine Operator Concentration — Top 6 Share
Operator disclosures, hospital programme websites, lab filings, Insight Research triangulation
Thailand Clinical NGS Oncology Panel Cost-of-Goods (50-gene panel)
Lab operator filings, Asia Genomics, Quantum Tech), reagent supplier benchmarks, Insight Research triangulation
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.